Margaret Ashton-Key
Novel and mutation and distinct genetic profiles in MALT lymphomas of different sites
Moody S, Goodlad J, Bi Y, Ashton-Key M, Robson A, Cogliatti S, Wu F, Wlodarska I, Vassiliou G, Raderer M, Liu H, Chuang S, Thompson J, Du M. Novel and mutation and distinct genetic profiles in MALT lymphomas of different sites. Haematologica 2018; 103:1329-1336.
Apr 19, 2018Novel and mutation and distinct genetic profiles in MALT lymphomas of different sites
Apr 19, 2018Haematologica 2018; 103:1329-1336
Moody Sarah, Goodlad John, Bi Yingwen, Ashton-Key Margaret, Robson Alistair, Cogliatti Sergio B., Wu Fangtian, Wlodarska Iwona, Vassiliou George, Raderer Markus, Liu Hongxiang, Chuang Shih-Sung, Thompson Joe Sneath, Du Ming-Qing
Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma
Moody S, Bi Y, Raderer M, Ashton-Key M, Goodlad J, Liu H, Cogliatti S, Chuang S, Robson A, Zeng N, Xue X, Dunn-Walters D, Ochoa Ruiz E, Clipson A, Wang M, Escudero-Ibarz L, Du M. Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma. J Pathol 2017; 243:3-8.
Aug 7, 2017Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma
Aug 7, 2017J Pathol 2017; 243:3-8
Moody Sarah, Bi Yingwen, Raderer Markus, Ashton-Key Margaret, Goodlad John, Liu Hongxiang, Cogliatti Sergio B., Chuang Shih-Sung, Robson Alistair, Zeng Naiyan, Xue Xuemin, Dunn-Walters Deborah, Ochoa Ruiz Eguzkine, Clipson Alexandra, Wang Ming, Escudero-Ibarz Leire, Du Ming-Qing
Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98)
Lee C, Ashton-Key M, Cogliatti S, Rondeau S, Schmitz S, Ghielmini M, Cragg M, Johnson P. Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98). Br J Haematol 2014; 168:145-8.
Aug 21, 2014Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98)
Aug 21, 2014Br J Haematol 2014; 168:145-8
Lee Chern Siang, Ashton-Key Margaret, Cogliatti Sergio B., Rondeau Stephanie, Schmitz Shu-Fang Hsu, Ghielmini Michele, Cragg Mark S, Johnson Peter